Meeting
2023 ASCO Annual Meeting
Economic evaluation for the US of durvalumab plus gemcitabine and cisplatin (DGC) in advanced biliary tract cancer (BTC).
Authors
Osama Aqel
Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ
Osama Aqel , Yunrong Shen , Ibrahim Alfayoumi , Ivo Abraham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4081)
DOI
10.1200/JCO.2023.41.16_suppl.4081
Abstract #
4081
Poster Bd #
402
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.
First Author: Mohamed Bouattour
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.
First Author: Taro Shibuki
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study.
First Author: Aiwu He
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Cost-effectiveness of gemcitabine plus cisplatin with and without durvalumab in patients with advanced cholangiocarcinoma.
First Author: J. Alberto Maldonado